Artal Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Artal Group’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-150,000	Closed	-$1.86M	–	109
2013 Q4	$1.86M	Buy	+150,000	New	+$1.51M	0.07%	80

Other funds holding VNDA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Artal Group's VNDA Position: Q1 2014 in Review

Artal Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2014, closing a stake of 150,000 shares — an estimated $1.86M sold.

Artal Group first reported a position in VNDA in Q4 2013 and held it in 1 quarter. The position peaked at $1.86M in Q4 2013. 109 funds tracked by Wall St. Rank hold VNDA as of Q1 2014.

Artal Group reported no remaining Vanda Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
Artal Group sold 150,000 Vanda Pharmaceuticals shares in Q1 2014, an estimated $1.86M.
Artal Group first reported a position in Vanda Pharmaceuticals in Q4 2013 and held it in 1 quarter.
Artal Group's Vanda Pharmaceuticals position peaked at $1.86M in Q4 2013.
109 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2014.

Based on Artal Group's 13F filing for Q1 2014, filed 15 May 2014.